Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4938028 | 0.99 | CXCR4 (0.93) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL24041209 | 0.99 | CXCR4 (0.93) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4932555 | 0.99 | CXCR4 (0.93) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4939469 | 0.97 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4932260 | 0.97 | CXCR4 (1.00) | CXCR4CHRM2CYP2D6DRD2OPRM1 | |
| SCHEMBL4936270 | 0.94 | CXCR4 (0.90) | CXCR4KCNH2 | |
| SCHEMBL4936161 | 0.90 | CXCR4 (0.81) | CXCR4KCNH2 | |
| SCHEMBL4939918 | 0.90 | CXCR4 (0.81) | CXCR4KCNH2 | |
| SCHEMBL4938814 | 0.90 | CXCR4 (0.83) | CXCR4KCNH2 | |
| SCHEMBL4940042 | 0.90 | CXCR4 (0.83) | CXCR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778231-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-06-03 | — | — | EP | claimed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | claimed |
| EP-1778231-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006020415-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-23 | — | — | WO | claimed |
| US-20200199683-A1 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20160222465-A1 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160222465-A1 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-04 | — | — | US | disclosed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096861-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199683-A1 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | BCL6, IGLV6-57, BCL6B | CXCR4 1090/4885CHRM2 4231/4885CYP2D6 3733/4885 |
| US-20160222465-A1 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | BCL6, IGLV6-57, BCL6B | CXCR4 1090/4885CHRM2 4231/4885CYP2D6 3733/4885 |
| US-20080096861-A1 | Chemical Compounds | CCR5, CXCR4, CXCR3 | CXCR4 2/4885CHRM2 3578/4885CYP2D6 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.